/190A.T

190A.T Stock - Chordia Therapeutics Inc.

Q: What is the analyst price target for 190A.T?

Analyst price target information is not currently available for 190A.T.

Q: What is 190A.T's market cap?

Market capitalization information is not currently available for 190A.T.

Healthcare|Medical - Pharmaceuticals|JPX

$106.00+0.00%

+$0.00 (+0.00%) • Dec 24

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $116.60

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for 190A.T

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

FY2025

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-3.08

52W High$457.00

52W Low$98.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	N/A	N/A	$2.50B	N/A	$800.00M
Gross Profit	$-1,425,309,000	$-4,095,000	$503.18M	$-3,147,000	$800.00M
Gross Margin	N/A	N/A	20.1%	N/A	100.0%
Operating Income	$-1,789,781,000	$-1,801,395,000	$212.06M	$-1,844,115,000	$-587,667,000
Net Income	$-1,785,867,000	$-1,827,127,000	$223.34M	$-1,779,060,000	$-527,107,000
Net Margin	N/A	N/A	8.9%	N/A	-65.9%
EPS	$-26.03	$-31.11	$3.96	$-39.78	$-15.08

Company Overview

Chordia is focused on the oncology area, with its target areas ranging from exploratory research to Proof of Concept (POC). For subsequent business development, we will build a system that allows us to make the best choices for maximizing corporate value, such as out-licensing and joint development and sales.

Visit Website

Earnings History & Surprises

190A.T

Beat Rate

Last 0 quarters

Avg Surprise

+0%

EPS vs Estimate

Beats / Misses

0/0

Last 12 quarters

Latest EPS

$-5.60

Q4 2025

EPS Surprise History

Q3 23

No data

Q3 24

No data

Q4 24

No data

Q1 25

No data

Q2 25

No data

Q4 25

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2025	Oct 14, 2025	—	$-5.60	—	—
Q2 2025	Apr 11, 2025	—	$-5.25	—	—
Q1 2025	Jan 14, 2025	—	$-9.07	—	—
Q4 2024	Oct 11, 2024	—	$-6.64	—	—
Q3 2024	Aug 31, 2024	—	$-9.60	—	—
Q3 2023	Aug 30, 2023	—	$-9.30	—	—

Frequently Asked Questions about 190A.T

What is 190A.T's current stock price?

Chordia Therapeutics Inc. (190A.T) is currently trading at $106.00 per share. The stock has moved +0.00% today.

What is the analyst price target for 190A.T?

No analyst price targets are currently available for this stock.

What sector is Chordia Therapeutics Inc. in?

Chordia Therapeutics Inc. operates in the Healthcare sector, specifically within the Medical - Pharmaceuticals industry. The company is traded on the JPX exchange.

What is 190A.T's market cap?

Chordia Therapeutics Inc. has a market capitalization of $7.31 billion, making it a mid-cap company.

Does 190A.T pay dividends?

No, Chordia Therapeutics Inc. does not currently pay a dividend to shareholders.